可调控膜结合 IL-15 工程化 TIL 疗法在免疫检查点抑制剂耐药晚期黑色素瘤中的 Phase 1 与 1/2 期试验汇总分析
Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
Nature Medicine 发表两项试验的非预设汇总分析，评估工程化自体肿瘤浸润淋巴细胞疗法 amsokigene autoleucel 在免疫检查点抑制剂难治性黑色素瘤患者中的表现。该疗法经改造以消除对 IL-2 的依赖，研究显示其可成功制备、耐受性良好，并呈现初步临床疗效信号。结果已在 Society for Immunotherapy of Cancer 2026 年年会上公布。
Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04743-6
As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-infiltrating lymphocyte therapy engineered to eliminate the need for IL-2, was successfully manufactured and well tolerated and showed a preliminary clinical efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.
来源：Nature Medicine · nature.com